Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2024

Open Access 01-12-2024 | Mood Disorders | Research

Value-based pricing of cognitive behavioral therapy for depression in primary care: an economic evaluation

Author: Afschin Gandjour

Published in: BMC Health Services Research | Issue 1/2024

Login to get access

Abstract

Objectives

Value-based pricing (VBP) determines product prices based on their perceived benefits. In healthcare, VBP prices medical technologies considering health outcomes and other relevant factors. This study applies VBP using economic evaluation to provider-patient communication, taking cognitive behavioral therapy (CBT) for adult primary care patients with depressive disorders as a case study.

Methods

A 12-week decision-tree model was developed from the German social health insurance system’s perspective, comparing CBT against the standard of care. The influence of an extended time horizon on VBP was assessed using a theoretical model and long-term data spanning 46 months.

Results

Using a willingness-to-pay threshold of €88,000 per quality-adjusted life year gained, the base-case 50-minute compensation rate for CBT was €45. Assuming long-term effects of CBT significantly affected the value-based compensation, increasing it to €226.

Conclusions

This study showcases the potential of applying VBP to CBT. However, significant price variability is highlighted, contingent upon assumptions regarding CBT’s long-term impacts.
Literature
1.
McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733–44.CrossRefPubMed
2.
3.
4.
5.
6.
Bretschneider J, Kuhnert R, Hapke U. Depressive Symptomatik bei Erwachsenen in Deutschland. J Health Monit. 2017;2(3):81–8.
7.
Statistisches Bundesamt. Gesundheit: Krankheitskosten. Fachserie 12 Reihe 7.2.1. Wiesbaden: Statistisches Bundesamt; 2017.
8.
Gandjour A, Chernyak N. A new prize system for drug innovation. Health Policy. 2011;102(2–3):170–7.CrossRefPubMed
9.
10.
Kuntz KM, Russell LB, Owens DK, Sanders GD, Trikalinos TA, Salomon JA. (2016). Decision models in cost-effectiveness analysis. In: Neumann, P. J., Sanders, G. D., Russell, L. B., Siegel, J. E., & Ganiats, T. G, editors. Cost-effectiveness in health and medicine. Oxford University Press; 2016.
11.
Pearson SD, Ollendorf DA, Chapman RH. New cost-effectiveness methods to determine value-based prices for potential cures: what are the options? Value Health. 2019;22(6):656–60.CrossRefPubMed
12.
Santoft F, Axelsson E, Öst LG, Hedman-Lagerlöf M, Fust J, Hedman-Lagerlöf E. Cognitive behaviour therapy for depression in primary care: systematic review and meta-analysis. Psychol Med. 2019;49(8):1266–74.CrossRefPubMed
13.
Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.CrossRefPubMedPubMedCentral
14.
15.
16.
Kolovos S, Bosmans JE, van Dongen JM, van Esveld B, Magai D, van Straten A, van der Feltz-Cornelis C, van Steenbergen-Weijenburg KM, Huijbregts KM, van Marwijk H, Riper H, van Tulder MW. Utility scores for different health states related to depression: individual participant data analysis. Qual Life Res. 2017;26(7):1649–58.CrossRefPubMedPubMedCentral
17.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen. Abschlussbericht G09-01. Köln; 2013.
18.
19.
Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL). Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen Nach § 35a SGB V– Vortioxetin. Berlin: Gemeinsamer Bundesausschuss; 2015.
20.
Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. J R Soc Med. 2017;110(10):404–10.CrossRefPubMedPubMedCentral
21.
Ross EL, Zuromski KL, Reis BY, Nock MK, Kessler RC, Smoller JW. Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US. JAMA Psychiatry. 2021 Mar;17:e210089.
22.
23.
Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–62.CrossRefPubMed
24.
Saylan M, Treur MJ, Postema R, Dilbaz N, Savas H, Heeg BM, Drost PB. Cost-effectiveness analysis of aripiprazole augmentation treatment of patients with major depressive disorder compared to olanzapine and quetiapine augmentation in Turkey: a microsimulation approach. Value Health Reg Issues. 2013 Sep-Oct;2(2):171–80.
25.
Wiles NJ, Thomas L, Turner N, Garfield K, Kounali D, Campbell J, Kessler D, Kuyken W, Lewis G, Morrison J, Williams C, Peters TJ, Hollinghurst S. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. Lancet Psychiatry. 2016;3(2):137–44.CrossRefPubMed
26.
27.
Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001 Jan-Feb;4(1):16–31.
28.
Gandjour A, Lauterbach KW. When is it worth introducing a quality improvement program? A mathematical model. Med Decis Mak. 2003 Nov-Dec;23(6):518–25.
29.
Kulp W, von der Schulenburg JM, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ. 2005;6(4):317–21.CrossRefPubMed
30.
Wunsch EM, Kliem S, Grocholewski A, Kröger C. Wie teuer wird es wirklich? Kosten-Nutzen-Analyse für Psychotherapie bei Angst- und affektiven Störungen in Deutschland. Psychol Rundsch. 2013;64(2):75–93.CrossRef
31.
Biddle L, Miners A, Bozorgmehr K. Cost-utility of screening for depression among asylum seekers: a modelling study in Germany. Health Policy. 2019;123(9):873–81.CrossRefPubMed
32.
Baumann M, Stargardt T, Frey S. Cost-utility of internet-based cognitive behavioral therapy in unipolar depression: a Markov model simulation. Appl Health Econ Health Policy. 2020;18(4):567–78.CrossRefPubMedPubMedCentral
33.
Cuijpers P, Karyotaki E, de Wit L, Ebert DD. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. Psychother Res 2019 Aug 8:1–15.
34.
Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52(10):850–6.CrossRefPubMed
35.
Wagner CJ, Metzger FG, Sievers C, Marschall U, L’Hoest H, Stollenwerk B, Stock S. Depression-related treatment and costs in Germany: do they change with comorbidity? A claims data analysis. J Affect Disord. 2016;193:257–66.CrossRefPubMed
36.
Metadata
Title
Value-based pricing of cognitive behavioral therapy for depression in primary care: an economic evaluation
Author
Afschin Gandjour
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2024
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-024-10653-5

Other articles of this Issue 1/2024

BMC Health Services Research 1/2024 Go to the issue

Research

Grace Under Pressure: a mixed methods impact assessment of a verbatim theatre intervention to improve healthcare workplace culture

Research

Healthcare worker burnout: exploring the experiences of doctors working in a maternity unit in Namibia

Research

How external and agency characteristics are related to coordination in homecare – findings of the national multicenter, cross-sectional SPOTnat study

Research

Experiences of delivering and receiving mental healthcare in the acute hospital setting: a qualitative study

Research

Physicians’ irrational attitudes on the antibiotic prescribing for the treatment of COVID-19 in Turkey: A multicenter survey

Research

Development of regional pharmacy intravenous admixture services data reporting and analysis platform for enhanced quality control ability